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Six hundred diarrheal stool specimens were collected from inpatients and outpatients at local university
hospitals for the detection of toxigenic Clostridium difficile using three parallel methods, the BD GeneOhm
Cdiff assay, the tissue culture cytotoxicity assay, and a commercially available enzyme-linked fluorescence
immunoassay (ELFA) (Vidas C. difficile toxin A and B assay; bioMe´rieux). Toxigenic C. difficile culture was
also performed to further clarify discordant results. During a 3-month study period, 58 (9.7%) of the 600
diarrheal samples examined were positive by the BD GeneOhm Cdiff assay, while the Vidas C. difficile toxin
A and B assay and the cytotoxicity assay performed directly on stool samples gave 4.7% and 6.3% positivity
rates, respectively. In the case of four samples, BD GeneOhm Cdiff assay results were not evaluable at first
because of the presence of PCR inhibitors, but upon repeat testing from the frozen lysates, all of these
samples proved to be negative. After resolution with toxigenic culture, the cytotoxicity assay proved to be
positive in 55 samples (9.2%), while the ELFA was positive in 37 samples (6.2%). Results of culture and
repeated cytotoxicity assays emphasized the importance of the culture method, because the use of ELFA
or enzyme immunoassay without a culture method may lead to a substantial portion of toxigenic C. difficile
strains being missed.
Toxin-producing Clostridium difficile strains are important
pathogens among patients who are treated with antibiotics or
chemotherapeutic agents not only in the hospital environment
but also in the community (3, 6, 10). Since the recognition of
outbreaks of C. difficile infection (CDI) caused by C. difficile
PCR ribotype 027 in Canada, the United States, and several
European countries, rapid and accurate diagnosis of CDI is
very important to stop the spread of these strains (7, 8, 19). In
addition, the increasing morbidity and mortality rates associ-
ated with CDI and the increasing number of recurrences and
therapeutic failures also highlight the need for the develop-
ment of a rapid and reliable detection method for toxigenic C.
difficile in diarrheal feces (12).
Only a few laboratories routinely use the tissue culture cy-
totoxicity and toxin neutralization assays for the detection of
toxigenic C. difficile in feces, because they are labor-intensive
and time-consuming and standardization is very difficult. Due
to their rapid turnaround time, enzyme immunoassays (EIAs)
that detect toxin A and/or toxin B in stool are used in most
laboratories (11, 16). To increase the sensitivity of these tests
and in some instances to facilitate epidemiological investiga-
tions, culture of C. difficile has become essential. In spite of
this, most laboratories use a single toxin detection test on feces
for detection of toxigenic C. difficile (4). In the last 10 years,
in-house PCR and real-time PCR assays have been developed
to detect C. difficile toxin genes. These assays have shown very
good sensitivity and specificity and short turnaround times (1,
17). However, widespread use of PCR methods in routine
clinical microbiology is limited because these tests require spe-
cial DNA extraction procedures to eliminate PCR inhibitors
from fecal specimens and they cost more than do traditional
testing methods.
The BD GeneOhm Cdiff assay provides a rapid method for
the qualitative detection of the C. difficile toxin B gene (tcdB)
in diarrheal specimens from patients suspected of having CDI.
This test is based on the amplification of the tcdB gene and the
detection of the amplified DNA using fluorogen-labeled
probes. Amplification, detection, and interpretation of the re-
sults are done automatically by the SmartCycler instrument
(Cepheid, Sunnyvale, CA).
Our aims were to compare the performance of the BD
GeneOhm Cdiff assay to those of the tissue culture cytotoxicity
assay and a commercially available enzyme-linked fluorescence
immunoassay (ELFA) (Vidas C. difficile toxin A and B assay;
bioMe´rieux, Marcy-l’Etoile, France), for the direct detection
of toxins A and B from fecal samples.
MATERIALS AND METHODS
Stool specimens. Six hundred diarrheal stool specimens were collected from
inpatients and outpatients in the local university hospital during a 3-month
period. The samples were submitted by physicians to the laboratory for routine
C. difficile testing by toxin A/B EIA, on the suspicion that these patients had CDI.
On arrival at the laboratory, the stool samples were immediately tested by the
ELFA (Vidas C. difficile toxin A and B assay; bioMe´rieux, Marcy-l’Etoile,
France) and culture and were stored at 4°C for testing within 5 days by the BD
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GeneOhm Cdiff assay and tissue culture cytotoxicity assay. The molecular
method, the ELFA, the cytotoxicity assay, and culture were performed by three
persons blinded to the results of other tests during this study, and a second
reader also evaluated the cytotoxic activity.
C. difficile toxin detection using the ELFA method. The Vidas C. difficile toxin
A and B assay (bioMe´rieux, Marcy-l’Etoile, France) was used for the detection
of toxins A and B directly from diarrheal stool samples and culture, and the
results were available within 3 h of receipt in the laboratory.
Cytotoxicity assay on HeLa cell line. The tissue culture cytotoxicity assay was
performed on all diarrheal samples using the HeLa cell line. Stool specimens
were diluted in phosphate-buffered saline buffer (1:10, wt/vol) and then centri-
fuged at 12,000 rpm for 10 min. The supernatant was filtered through a 0.22-
m-pore-size membrane filter (Millex-GV; Millipore Co. Ltd., Billerica, MA).
Twenty microliters of filtered supernatant was transferred onto the HeLa cell
line grown at 37°C in Dulbecco’s modified Eagle’s medium (Sigma, St. Louis,
MO) supplemented with 10% heat-inactivated fetal bovine serum in a 96-well
microtiter plate. Prior to testing for cytotoxicity, the cell culture medium was
removed and fresh medium was added without serum. The plates were incubated
at 37°C for 24 h in 5% CO2 to confirm any observed cytopathic effect; toxin
neutralization with C. difficile goat antitoxin serum was performed (9). Broth
culture of the reference strain VPI 10463 (ATCC 43255, toxinotype 0) obtained
from the American Type Culture Collection (Manassas, VA) was used as a
positive control in the cytotoxicity assay.
BD GeneOhm Cdiff assay. The BD GeneOhm Cdiff assay was performed
according to the manufacturer’s instructions. Briefly, the diarrheal stool speci-
men was vortexed at high speed and transferred to the sample buffer provided by
the manufacturer by using a dry sterile swab. The tightly closed tube containing
the broken swab was vortexed at high speed for 1 min. Forty microliters of
sample buffer was transferred to the lysis tube, and 10 l of the vortexed stool
specimens was transferred to this tube. The lysis tube was vortexed at high speed
for 5 min, after which it was centrifuged for about 5 s to collect the contents at
the bottom of this tube. The lysis tube was incubated at 95°C for 5 min and placed
immediately on ice. Two hundred twenty-five microliters of diluent was added to
the Master Mix tube (provided by the manufacturer), to prepare a reaction mix
sufficient for eight reactions including one negative and one positive control. The
positive and negative controls were each dissolved in 225 l sample buffer.
Twenty-five microliters of Master Mix was transferred to each SmartCycler tube
in a cooling block, and 3 l of each lysed specimen and positive and negative
controls was added to the labeled SmartCycler tubes. The tubes were centrifuged
for 10 s and placed into an I-Core of the SmartCycler instrument.
Culture of C. difficile. All diarrheal samples were cultured on selective medium
(C. difficile agar base supplemented with 7% [vol/vol] defibrinated horse blood,
250 mg/liter cycloserine, and 8 mg/liter cefoxitin) (Oxoid), and the plates were
incubated at 37°C for 48 h under anaerobic conditions (85% N2, 10% CO2, 5%
H2; Bactron; Sheldon Manufacturing Inc.). The culture isolates were identified
on the basis of characteristic C. difficile colony morphology, odor, fluorescence,
and Gram stain; in the case of any discrepancy, the API 20A (bioMe´rieux,
Marcy-l’Etoile, France) identification system was used. Pure isolated C. difficile
colonies were subcultured in chopped meat broth and incubated for 48 h under
anaerobic conditions. The supernatant was tested using the tissue culture cyto-
toxicity assay on the HeLa cell line; this was considered a toxigenic culture.
RESULTS
A total of 600 diarrheal feces samples collected from inpa-
tients and outpatients were examined for the presence of tox-
igenic C. difficile. Initially, four samples were inhibitory to
PCR, but upon repeat testing of samples from frozen lysates,
all of these samples proved to be negative. During the study
period, 9.7% of the specimens were positive by the BD
GeneOhm Cdiff assay. The tissue culture cytotoxicity assay and
the Vidas C. difficile toxin A and B assay had positivity rates of
6.3% and 4.7%, respectively, from direct testing of stool sam-
ples. On initial testing, 36 samples (6%) were positive and 536
(90%) were negative by the BD GeneOhm Cdiff assay and the
tissue culture cytotoxicity assay (Table 1). Samples with results
discordant between the two methods were resolved by toxi-
genic culture. Seventeen samples which were positive by the
BD GeneOhm Cdiff assay but negative by the cytotoxicity assay
were confirmed as truly positive by toxigenic culture (Table 1).
In five cases, the BD GeneOhm Cdiff assay gave positive re-
sults while the cytotoxicity assay and toxigenic culture were
negative. Two samples were positive by the cytotoxicity assay
but negative by the BD GeneOhm Cdiff assay; these were
confirmed as true positives by toxigenic culture. With the use
of the tissue culture cytotoxicity assay and resolution of dis-
cordant specimens with toxigenic culture, the sensitivity, spec-
ificity, and positive and negative predictive values (PPV and
NPV, respectively) of the BD GeneOhm Cdiff assay after dis-
cordant result analysis were 96.4%, 99.1%, 92%, and 100%,
respectively (Table 1).
Of the 600 samples, 39 gave equivocal results by the Vidas C.
difficile toxin A and B assay; in these cases cytotoxicity assay
and culture were used to confirm these results (Table 2). Of 39
diarrheal samples, 30 proved to be negative by the BD
GeneOhm Cdiff assay, cytotoxicity test, and culture, while nine
specimens gave positive results by real-time PCR and toxigenic
culture (Table 2). Concordant results were observed for 20
positive and 500 negative samples (Table 2). Six samples were
positive by only the Vidas C. difficile toxin A and B assay.
Nontoxigenic C. difficile strains were isolated from 19 diar-
rheal samples; these samples were negative by the BD
GeneOhm Cdiff assay and Vidas C. difficile toxin A and B
assay. The majority of toxin-positive samples were collected
from patients in the intensive care unit (34.6%). Two out of
eight samples from the dermatology unit and one out of four
samples from the surgery department proved to be positive for
TABLE 1. Comparison of the BD GeneOhm Cdiff assay to the
tissue culture cytotoxicity assay for detection of toxigenic C. difficile
from diarrheal stool after initial testing and after resolution
with toxigenic culture and upon repeat PCR testing
from frozen lysates
PCR
result
type
No. of results for cytotoxicity assay
Initial results After resolution withtoxigenic culture
Positive Negative Total Positive Negative Total
Positive 36 22 58 53 5 58
Negative 2 536 538 2 540 542
Total 38 558 596 55 545 600
TABLE 2. Comparison of the BD GeneOhm Cdiff assay to the
Vidas C. difficile toxin A and B assay for detection of toxigenic
C. difficile from diarrheal stool after initial testing and after
resolution with toxigenic culture and upon repeat PCR
testing from frozen lysates
PCR
result
type
No. of results of toxin A and B assay
Initial results After resolution withtoxigenic culture
Positive Equivocal Negative Positive Negative Total
Positive 20 9 29 29 29 58
Negative 8 30 500 8 534 542
Total 37 563 600
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toxigenic C. difficile; these represented units in which physi-
cians usually request insufficiently low numbers of C. difficile
tests as part of the routine enteric laboratory diagnostic testing.
DISCUSSION
On the basis of our results and those of Stamper et al., the
BD GeneOhm Cdiff assay provides better sensitivity and spec-
ificity for the detection of C. difficile than do toxin A/B enzyme-
linked immunosorbent assays directly from diarrheal stool
specimens (15). In addition, the prevalence of positive samples
directly from stool by real-time PCR was higher (9.7%) than in
the case of the cytotoxicity assay (6.3%), which is considered
the “gold standard” for the detection of toxigenic C. difficile.
The overall prevalence of toxin-producing C. difficile strains
determined by toxigenic culture (i.e., culture plus cytotoxicity
assay) was 9.2%. These results emphasized the importance of
culture method, because 2.9% of toxigenic C. difficile strains
were detected from broth culture, and the cytotoxicity assay
gave false-negative results directly from stool; thus, these di-
rect-cytotoxin-negative but cytotoxigenic-culture-positive sam-
ples represent true CDI cases. In addition, the cytotoxicity test
for the detection of toxigenic C. difficile is available only once
or twice per week, and in these cases, pure broth culture of the
isolated strain required setup of the test, which meant an
additional delay in the diagnosis of CDI of at least 4 days. The
five samples that were positive only by the BD GeneOhm Cdiff
assay and from which C. difficile could not be isolated could be
considered false positive by PCR. However, the presence of
toxigenic C. difficile in these samples cannot be excluded com-
pletely, because the stringent requirements for anaerobic cul-
ture and the alcohol shock treatment during sample processing
may have reduced the number of viable bacteria and spores
and led to culture failure; in these cases, further confirmation
would be necessary to determine whether these samples are
false or true positives. The six samples that were positive only
by the Vidas C. difficile toxin A and B assay may be due to the
cross-reactivity with Clostridium sordellii toxin; however, there
is no evidence for this, or perhaps this result simply represents
poor specificity of the EIA. A relatively high number of di-
arrheal samples (5%) showed equivocal results by the Vidas
assay; in these cases, the cytotoxicity assay and culture or
new sample collection may provide more reliable results.
The superior performance of the BD GeneOhm Cdiff assay
was shown in two cases in which the PCR assay gave positive
results earlier than did the Vidas C. difficile toxin A and B
assay. Case 1 was a 39-year-old male patient who had antibi-
otic-associated diarrhea after an appendectomy. His first diar-
rheal sample was submitted for laboratory testing on 3 Novem-
ber 2008, at which time the BD GeneOhm Cdiff assay, the
cytotoxicity assay, and culture results for toxigenic C. difficile
were all positive; but the Vidas C. difficile toxin A and B assay
was negative. Because of persistent diarrhea, detection of tox-
ins A and B was performed 10 days later, after the patient had
been discharged from the hospital, by the Vidas C. difficile
toxin A and B assay, which gave a positive result. In case 2, a
75-year-old patient was treated in the infectious disease unit
for severe diarrhea. Four samples were sent to our laboratory
(on 5, 14, and 27 October 2008 and 13 November 2008) for
detection of toxigenic C. difficile because of persistent diarrhea
despite the adequate antibiotic therapy. Three samples were
negative, and one sample gave an equivocal result with the
Vidas toxin A/B assay. The cytotoxicity assay result from direct
stool testing was positive on 5 and 27 October. In contrast, all
four specimens were positive by the BD GeneOhm Cdiff assay.
C. difficile was grown from all samples, and toxin production
was confirmed by the cytotoxicity assay.
Several studies have demonstrated the performance of PCR
or real-time PCR assays for the detection of C. difficile genes
from diarrheal stool samples (2, 5, 13, 14, 17, 18). In 2002,
Guilbault et al. used PCR for the detection of the nonrepeat-
ing region of the tcdB gene from 59 stool specimens (5). Com-
pared to the reference cytotoxicity assay, this method demon-
strated 100% specificity and 91.5% sensitivity, results were
available within 6 h, and none of the samples tested were
inhibited (5). Be´langer et al. later developed a real-time PCR
assay targeting the major toxin genes (tcdA and tcdB) (2). The
turnaround time including sample preparation was about 1.5 h,
and the assay was about 100-fold more sensitive than the PCR
method described by Guilbault et al. (2, 5). van den Berg et al.
published two studies using real-time PCR assays for the de-
tection of the tcdB gene (17, 18). However, compared with the
cytotoxicity assay, the sensitivity and the specificity of this test
(87.1% and 96.5%, respectively) were lower than the observa-
tions by Guilbault et al. and showed the highest concordance
with toxigenic culture (5, 17, 18). These studies showed that a
remarkable number of samples were positive by immunoassay
but were negative by tissue culture cytotoxicity, toxigenic cul-
ture, and real-time PCR. In our study, six samples (1%) were
false positive by the Vidas C. difficile toxin A and B assay, and
the number of equivocal results was quite high. This was of
concern because not only can this delay accurate diagnosis of
C. difficile-associated disease but also it is associated with a
higher cost due to the repeated testing or a new sample col-
lection. Similar sensitivity and specificity (86% and 97%, re-
spectively) were found by Sloan et al. in a study where real-
time PCR was applied for the detection of the tcdC gene and
compared to toxigenic culture (14).
Stamper et al. examined 404 stool samples using the BD
GeneOhm Cdiff assay, the cell culture cytotoxicity assay, and
toxigenic culture, and the prevalence of positive specimens was
10% by both PCR and cytotoxin production (15). Compared
with the cytotoxicity assay as the reference method, the sensi-
tivity, specificity, PPV, and NPV of the BD GeneOhm Cdiff
assay were 90.9%, 95.2%, 70.2% and 98.8%, respectively. In
our study, the following results were obtained: the sensitivity,
specificity, PPV, and NPV were 96.4%, 99.01%, 92%, and
100%, respectively. The PCR inhibition rate in our study was
0.6% (4/600); similarly, Stamper et al. detected inhibitors in
three samples. Two samples in our study were negative by only
real-time PCR, while cytotoxicity and Vidas assays and toxi-
genic culture were positive; similar findings were reported by
Stamper et al., who found four samples which proved to be
negative by real-time PCR. A possible explanation of this is
that some strains may carry an aberrant tcdB gene, and this
may result in the failure of primer annealing, or the copies of
the target in the stool sample were below the detection limit of
the PCR assay.
Although the cost of the BD GeneOhm Cdiff assay is higher
than that of immunoassays, the use of a more sensitive test can
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provide more reliable results for detection of toxigenic C. dif-
ficile. With prompt and accurate diagnosis of CDI, the total
cost of the hospital care and the duration of patient hospital-
ization may be reduced. In addition, unnecessary antibiotic
therapy may be avoided and the number of further possible
nosocomial infections may also decrease. Using the PCR assay,
it is also feasible to avoid false-negative, direct EIA results
originating from the possible degradation of C. difficile toxins
in fecal specimens. Specimens can be kept at room tempera-
ture up to 48 h before testing; thus, temperature does not
influence the test result within this period of time, which is very
important mainly if transport at 4°C is not available, e.g., in the
case of outpatients. The BD GeneOhm Cdiff assay contains an
internal control; thus, the presence of PCR-inhibitory sub-
stances can be detected too. The assay is cost-effective if at
least eight reactions including one positive and one negative
control are run, because reconstituted reagents remain stable
at 2 to 8°C for 3 h.
In conclusion, the BD GeneOhm Cdiff assay is a rapid and
reliable tool for detection of toxigenic C. difficile from diar-
rheal specimens and is superior to all known traditional meth-
ods such as the cytotoxicity assay, various immunoassays, and
in-house PCRs.
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